[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Labo'Life\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":112},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,65,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100386173","phase-4-study-to-evaluate-the-efficacy-of-2lebv-and-2lxfs-on-asthenia-in-patients-with-an-epstein-barr-virus-infection-100386173",false,"NCT04308278","Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection","Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection.","EBVAST","Pré-Inclusion Criteria:\n\n* Patients, male or female, aged 12 years and older,\n* Patient with fatigue for 1 month or more,\n* Patient with at least two other symptoms among the following: Long-lasting exhaustion even after light exertion, subfebrile state, fever, loss of appetite, nausea, angina, conjunctivis, sensitive cervical or axillary lymph nodes, erythematous and swollen tonsil, headaches, sore throat, myalgia, muscular weakness, arthralgia, splenomegaly, visual disorders, memory disorders, attention deficit disorders, sleep disorders, gastrointestinal disorders, breathing disorders, cardiovascular disorders.\n* Patient (and\u002For parents if necessary) agrees to perform serology for the study,\n* Patient (and\u002For parents if necessary) agrees to perform lymphocyte typing for the study during the pre-inclusion visit,\n* Patients (and\u002For parents if necessary) having the faculties to understand and respect the constraints of the study,\n* Signature of the Informed Consent Form by the patient (and\u002For parents if necessary).\n\nInclusion Criteria:\n\n\\- Patient who have a positive serology for EBV (IgG and\u002For IgM positive).\n\nExclusion Criteria:\n\n* Patient who have received any treatment with the 2LEBV® or 2LXFS®,\n* Patients who have received any homeopathic treatment in the previous 2 months prior to the study,\n* Patients under immunosuppressive treatment,\n* Patient undergoing treatment for psychiatric disorders,\n* Patients having received immunotherapy or micro-immunotherapy during the last 3 months,\n* Patients with known lactose intolerance,\n* Pregnant or breastfeeding women,\n* Patients who participated in a clinical study in the previous 2-months period,\n* Patients (and\u002For parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study,\n* Patients with severe immunodeficiency disease requiring long term treatment (\\*) or patients under chemotherapy or radiotherapy,\n* Patients under homeopathic or phytotherapy treatment,\n* Patients addicted to or using recreational drugs,\n* Patient under guardianship and\u002For curatorship, (\\*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV\u002FAIDS, terminal cancer.","ALL","12 Years",{"count":20,"type":21},88,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may cause different diseases. In most cases, EBV infection is asymptomatic because of a highly effective host immune response. Some individuals develop infectious mononucleosis (a self-limiting lymphoproliferative disorder in adolescents and young adults that is considered to be the primary infection), while others develop chronic fatigue syndrome, EBV-associated lymphoid, or epithelial malignancies.\n\nToday, there is no available treatment to treat and destroy EBV. The treatment is essentially symptomatic (treatment of the symptoms and not of the virus itself) with analgesics for pain for example.\n\nThe studied drugs are 2LEBV® and 2LXFS®, from Labo'Life company, and the treatment schema is the same for the two drugs: it consists in taking the content of one capsule per day, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment.\n\nThe duration of treatment will be of 6 months of continuous intake of the content of 1 capsule\u002Fday.\n\nThe aim of this study is to provide additional information on effectiveness on the 2LEBV® and 2LXFS®in the treatment of EBV chronic and acute infections, and in particular to demonstrate their effectiveness versus placebo in the reduction of asthenia and other symptoms in EBV infection.",[27],"EBV Infection","RECRUITING","2024-10-29",{"date":31,"type":32},"2024-10-30","ACTUAL",{"date":34,"type":32},"2021-01-22",{"date":36,"type":21},"2026-08-30",{"name":38,"class":39},"Labo'Life","INDUSTRY",12,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100380386","phase-4-study-of-2lpapi-on-the-clearance-of-genital-hr-hpv-infections-100380386","NCT04232917","Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.","Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections.","PAPION","Inclusion Criteria:\n\n* Women 25-45 years,\n* Women of childbearing age under effective contraception,\n* Patient with last cytology less than 3 years and normal or not more than LSIL or CIN I at the histology,\n* Patient with current cytology presenting normal, ASC-US, AGUS, LSIL, ASC-H, AGC or LSIL+ASC-H results or current diagnosis of CIN I at the histology,\n* Patient with HR-HPV diagnosis at the current cervical collection,\n* Patient reporting a current stable sexual relationship (steady sexual partner during study duration),\n* Patient having faculties to understand and respect the constraints of the study,\n* Signature of the Informed Consent Form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman,\n* Patient presenting HSIL diagnosis at the cytology or CIN II or CIN III diagnosis at the histology,\n* Patient having received HPV vaccination in the last month,\n* Patient previously subject to total hysterectomy,\n* Patient under immunotherapy (including immunosuppressive treatment) or micro-immunotherapy received during last previous 6 months,\n* Patient with known lactose intolerance,\n* Patient who participated in a clinical study in the previous 3-months' period,\n* Patient who is not sufficiently motivated to engage in a follow-up period of 12 months, or likely to travel or to move before the end of the study,\n* Patient with severe immunodeficiency disease requiring long term treatment (\\*) or under chemotherapy or radiotherapy,\n* Patient under listed homeopathic or phytotherapy treatment (see protocol),\n* Patient using or addicted to recreational drugs.\n\n(\\*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV\u002FAIDS, terminal cancer.","FEMALE","25 Years","45 Years",{"count":53,"type":21},284,[24],"Human papillomavirus (HPV) is a prevalent pathogen, the epidemiology of which has mostly been studied in the uterine cervix and the vagina.\n\nThe KCE Report 238Cs (2015) recommends \" HR-HPV-positive women should not be offered colposcopy immediately. Triage should be done using cytology for this purpose. If cytological abnormalities (ASCUS+) are found, immediate referral should follow for diagnosis and, where appropriate, treatment. If no abnormalities are observed in triage, the subject should be offered follow-up testing (cytology) at six months. \".\n\nThere is no treatment that is recommended during this lap time. The 2LPAPI® has been available for more than 20 years, and has received a marketing authorization in Belgium by the FAMHP. It is used as an immune regulator in the treatment of HR-HPV infections. Since 2LPAPI® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the clearance of HPV.\n\nThe purpose of this placebo-controlled trial is to evaluate the efficacy of 2LPAPI® on the clearance of genital HR-HPV infections.",[57],"Human Papilloma Virus",{"date":59,"type":32},"2024-10-31",{"date":61,"type":32},"2020-10-17",{"date":63,"type":21},"2027-10-30",{"name":38,"class":39},{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":81,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},"100367567","phase-4-randomized-placebo-controlled-double-blind-study-of-2lherp-in-orofacial-herpes-infections-100367567","NCT04065971","Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.","Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy of 2LHERP® in Patients With Recurrent Orofacial Herpes Infections.","HEARTH-OF","Inclusion Criteria:\n\n* Man or woman aged 16-80 years,\n* Patient presenting 6 or more episodes of orofacial herpes infections during the preceding 12-months' period (prior to the study entry),\n* Woman of childbearing age under effective contraception,\n* Patient reporting a current stable sexual relationship (steady sexual partner during study duration),\n* Patient having faculties to understand and respect the constraints of the study,\n* Signature of the Informed Consent Form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman,\n* Patient under immunotherapy (including immunosuppressive treatment) or micro-immunotherapy received during last previous 6 months,\n* Patient who had a suppressive antiviral therapy during last month,\n* Patient who wishes to continue his\u002Fher suppressive antiviral therapy,\n* Patient with known lactose intolerance,\n* Patient who participated in a clinical study in the previous 3-month period,\n* Patient who is not sufficiently motivated to engage in a follow-up period of 12 months, or likely to travel or to move before the end of the study,\n* Patient with severe immunodeficiency disease requiring long term treatment (\\*) or under chemotherapy or radiotherapy or corticoid therapy,\n* Patient under listed homeopathic or phytotherapy treatment,\n* Patient using or addicted to recreational drugs.\n\n(\\*) important renal or respiratory insufficiency, transplanted or grafted patients HIV\u002FAIDS, terminal cancer.","16 Years","80 Years",{"count":76,"type":21},140,[24],"Herpes simplex virus (HSV) infection is very common, as most people will experience herpetic infection during their lifetime. The most common manifestation of HSV infection is sores which may appear at any age.\n\nNo specific antiviral therapy is available to totally cure herpetic infections and today, there is no treatment that allows the definitive eradication of the virus.\n\nThe 2LHERP® has been available for more than 20 years, and has received a marketing authorization in Belgium by the FAMHP. It is used as an immune regulator in the treatment of herpetic infections. Since 2LHERP® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the disappearance of herpetic recurrences.\n\nThe purpose of this placebo-controlled trial is to evaluate the efficacy of 2LHERP® on the treatment of herpetic infections in adults.",[80],"Herpes Simplex",{"date":59,"type":32},{"date":83,"type":32},"2020-03-10",{"date":85,"type":21},"2027-03-31",{"name":38,"class":39},6,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":96,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":111},"100360793","phase-4-randomized-placebo-controlled-double-blind-study-to-evaluate-the-efficacy-of-2lverujunior-and-2lveru-on-the-treatment-of-warts-100360793","NCT03977753","Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts","Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts.","EVAsION","Inclusion Criteria:\n\n* Patients, male or female, aged 3 years and older,\n* Patients with common warts (Verruca vulgaris), and\u002For plantar warts (Verruca plantaris), and\u002For flat warts (Verruca plana),\n* Patients (and\u002For parents if necessary) having the faculties to understand and respect the constraints of the study,\n* Signature of the Informed Consent Form by the patient (and\u002For parents if necessary).\n\nExclusion Criteria:\n\n* Patients who have received any curative warts treatment in the previous 2 months prior to the study,\n* Patients who have received any homeopathic treatment in the previous 2 months prior to the study,\n* Patients under immunosuppressive treatment,\n* Patients having received immunotherapy or micro-immunotherapy during the last 6 months,\n* Patients with known lactose intolerance,\n* Pregnant or breastfeeding women,\n* Patients who participated in a clinical study in the previous 2-months period,\n* Patients (and\u002For parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study,\n* Patients with severe immunodeficiency disease requiring long term treatment (\\*) or patients under chemotherapy or radiotherapy,\n* Patients under listed homeopathic or phytotherapy treatment (see protocol),\n* Patients addicted to or using recreational drugs,\n* Patient under guardianship and\u002For curators, (\\*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV\u002FAIDS, terminal cancer.","3 Years",{"count":98,"type":21},162,[24],"Human papillomavirus (HPV) infection is very common, as most people will experience infection during their lifetime. The most common manifestation of HPV infection is common warts. Common warts may appear at any age.\n\nConventional treatments can be used to treat warts and they are based on two mechanisms: stimulation of cellular immunity against HPVs or destruction of the lesion. These treatments are based on the location of the wart and the degree of the symptoms.\n\nNo specific antiviral therapy is available to cure warts and today, there is no treatment that allows the definitive eradication of the virus.\n\nThe 2LVERU® has been available for more than 20 years, and has received a marketing authorization in Belgium by the Federal Agency for Medicines and Health Products (FAMHP). It is used as an immune regulator in the treatment of common warts (verruca vulgaris), flat warts (verruca plana) or plantar warts (verruca plantaris) caused by Human Papillomavirus. Since 2LVERU® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the disappearance of warts.\n\nThe purpose of this placebo-controlled, randomized, double-blind trial is the comparison of the efficacy of the treatment on the disappearance of warts at the end of treatment (6-month visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group.",[102,103,104],"Common Wart","Flat Wart","Plantar Wart",{"date":31,"type":32},{"date":107,"type":32},"2020-02-17",{"date":109,"type":21},"2027-03-16",{"name":38,"class":39},18,""]